Filtered By:
Specialty: Hematology
Condition: Heart Attack

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 519 results found since Jan 2013.

Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
Antiplatelet therapy is the cornerstone of secondary prevention against acute thrombotic events in patients with cardiovascular disease [1]. Health Organizations around the world recommend combination therapy with aspirin and a P2Y12 receptor inhibitor for up to one year following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), and lifelong aspirin therapy thereafter [2]. Vorapaxar, a first-in-class novel protease-activated receptor (PAR)-1 antagonist, was approved in addition to standard antiplatelet therapy, to further reduce the risk of myocardial infarction (MI), stroke, cardiovascular dea...
Source: Thrombosis Research - October 30, 2015 Category: Hematology Authors: Marie Lordkipanidzé Source Type: research

PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes
Abstract Clopidogrel and prasugrel are antiplatelet therapies commonly used to treat patients with cardiovascular disease. They are both pro-drugs requiring biotransformation into active metabolites. It has been proposed that a genetic variant Q192R (rs662 A>G) in PON1 significantly alters the biotransformation of clopidogrel and affects clinical outcomes; however, this assertion has limited support. The relationship between this variant and clinical outcomes with prasugrel has not been studied. We genotyped PON1 Q192R in 275 healthy subjects treated with clopidogrel or prasugrel and 2922 patients with an ACS u...
Source: Journal of Thrombosis and Thrombolysis - November 16, 2015 Category: Hematology Source Type: research

Global public awareness of venous thromboembolism: comment
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - November 1, 2015 Category: Hematology Authors: A. Aggarwal, F. R. Rickles Tags: Letter ‐ to the Editor Source Type: research

Global public awareness of venous thromboembolism: comment.
This article is protected by copyright. All rights reserved. PMID: 26663849 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 10, 2015 Category: Hematology Authors: Aggarwal A, Rickles FR Tags: J Thromb Haemost Source Type: research

High-sensitivity C-reactive protein and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes: a comparable and additive study
This study was designed to establish the relationship of high-sensitivity C-reactive protein (hsCRP) and mean platelet volume (MPV) with the development of adverse outcomes after percutaneous coronary intervention (PCI). hsCRP levels and MPV were analysed in 372 patients who underwent PCI, with the primary endpoint as major adverse cardiac and cerebrovascular events (MACCE): a composite of cardiac death, myocardial infarction (MI), target vessel revascularization (TVR), ischemic stroke and stent thrombosis. During the follow-up period (mean, 25.8 months), there were 21 cardiac deaths, 10 MIs including four stent thrombosis...
Source: Blood Coagulation and Fibrinolysis - January 1, 2016 Category: Hematology Tags: Original Articles Source Type: research

Atherosclerosis at arterial bifurcations: evidence for the role of haemodynamics and geometry.
Abstract Atherosclerotic plaques are found at distinct locations in the arterial system, despite the exposure to systemic risk factors of the entire vascular tree. From the study of arterial bifurcation regions, which are more prone to the initiation/progression of atherosclerosis, emerges ample evidence that haemodynamics are involved in the local onset and progression of the atherosclerotic disease. This observed co-localisation of disturbed flow regions and lesion prevalence at geometrically predisposed districts such as arterial bifurcations has led to the formulation of a 'haemodynamic hypothesis', that in th...
Source: Thrombosis and Haemostasis - January 7, 2016 Category: Hematology Authors: Morbiducci U, Kok AM, Kwak BR, Stone PH, Steinman DA, Wentzel JJ Tags: Thromb Haemost Source Type: research

Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction. Long-term results of the REVIVAL-2 trial.
In conclusion, these long-term follow-up data show that G-CSF does not improve clinical outcomes of patients with acute myocardial infarction. PMID: 26790705 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 21, 2016 Category: Hematology Authors: Steppich B, Hadamitzky M, Ibrahim T, Groha P, Schunkert H, Laugwitz KL, Kastrati A, Ott I, Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Study Investigators Tags: Thromb Haemost Source Type: research

Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism
The use of aspirin in the prevention of venous thromboembolism (VTE) is still controversial. In a profound review on the use of aspirin for primary and secondary prevention of venous thromboembolism and other cardiovascular disorders Cohen et al. [1] conclude that the benefits of aspirin are well documented for conditions like myocardial infarction, coronary heart disease, and stroke, but less clearly for prevention of VTE after orthopedic surgery. The latter indistinctness has been a matter of concern in many earlier reviews and meta-analyses, and has even led to non-uniform guidelines on VTE prevention from the American ...
Source: Thrombosis Research - January 27, 2016 Category: Hematology Authors: Piet Borgdorff, Geert Jan Tangelder Tags: Correspondence Source Type: research

Mesenchymal stem/stromal cell‐derived extracellular vesicles as a new approach in stem cell therapy
Mesenchymal stem or stromal cells (MSCs) are widely applied in regenerative and immune modulating therapies. Initially, it was assumed that administered MSCs integrate into damaged tissues to exert their clinical functions. However, in recent years accumulating evidence has been provided that MSCs rather act in a paracrine than a cellular manner. To this end, extracellular vesicles (EVs), which are secreted by MSCs in vivo and in vitro, seem to exert the MSCs’ therapeutic effects. So far, MSC‐EVs have been shown to improve functional recoveries following ischemic events, such as stroke and myocardial infarction, and to...
Source: ISBT Science Series - January 29, 2016 Category: Hematology Authors: V. Börger, M. Bremer, A. Görgens, B. Giebel Tags: Invited Review Source Type: research

Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Authors: Aksnes TA, Kjeldsen SE, Rostrup M, Holzhauer B, Hua TA, Julius S Abstract Diabetic and new-onset diabetic patients with hypertension have higher cardiac morbidity than patients without diabetes. We aimed to investigate whether baseline predictors of cardiac morbidity, the major constituent of the primary endpoint in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, were different in patients with diabetes and new-onset diabetes compared to patients without diabetes. In total, 15,245 high-risk hypertensive patients in the VALUE trial were followed for an average of 4.2 years. At baselin...
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research

Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis
Abstract As heart failure, coronary artery disease and atrial fibrillation all bring a risk of thrombosis, anti-thrombotic therapy is recommended. Despite such treatment, major cardiovascular events such as myocardial infarction and stroke still occur, implying inadequate suppression of thrombus formation. Accordingly, identification of patients whose haemostasis remains unimpaired by treatment is valuable. We compared indices for assessing thrombogenesis and fibrinolysis by two different techniques in patients on different anti-thrombotic agents, i.e. aspirin or warfarin. We determined fibrin clot formation and f...
Source: Journal of Thrombosis and Thrombolysis - March 4, 2016 Category: Hematology Source Type: research

Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta‐analysis of RCTs
This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - March 11, 2016 Category: Hematology Authors: Eric M. Ammann, Cole B. Haskins, Kelsey M. Fillman, Rebecca L. Ritter, Xiaomei Gu, Scott K. Winiecki, Ryan M. Carnahan, James C. Torner, Bruce H. Fireman, Michael P. Jones, Elizabeth A. Chrischilles Tags: Research Article Source Type: research

Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: One‐year outcomes from the GReek AntiPlatelet Registry (GRAPE)
ConclusionsIn real‐word ACS/PCI patients, prasugrel offered better antiischemic protection than clopidogrel, while use of both novel agents is accompanied by more frequent bleeding events.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 1, 2016 Category: Hematology Authors: D. Alexopoulos, I. Xanthopoulou, S. Deftereos, M. Hamilos, G. Sitafidis, I. Kanakakis, I. Pentara, M. Vavouranakis, P. Davlouros, G. Hahalis, J. Goudevenos Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: One-year outcomes from the GReek AntiPlatelet Registry (GRAPE).
CONCLUSIONS: In real-word ACS/PCI patients, prasugrel offered better antiischemic protection than clopidogrel, while use of both novel agents is accompanied by more frequent bleeding events. This article is protected by copyright. All rights reserved. PMID: 26990959 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 16, 2016 Category: Hematology Authors: Alexopoulos D, Xanthopoulou I, Deftereos S, Hamilos M, Sitafidis G, Kanakakis I, Pentara I, Vavouranakis M, Davlouros P, Hahalis G, Goudevenos J Tags: J Thromb Haemost Source Type: research

FXIIa inhibitor rHA‐Infestin‐4: Safe thromboprotection in experimental venous, arterial and foreign surface‐induced thrombosis
This study aimed to further assess the antithrombotic efficacy of the activated factor XII (FXIIa) inhibitor, rHA‐Infestin‐4, in several thrombosis models. In mice, rHA‐Infestin‐4 decreased occlusion rates in the mechanically‐induced arterial (Folt's) and the FeCl3‐induced venous thrombosis model. rHA‐Infestin‐4 also protected from FeCl3‐induced arterial thrombosis and from stasis‐prompted venous thrombosis in rabbits. Furthermore, rHA‐Infestin‐4 prevented occlusion in the arterio‐venous shunt model in mice and rabbits where thrombosis was induced via a foreign surface. In contrast to heparin, the...
Source: British Journal of Haematology - March 26, 2016 Category: Hematology Authors: Frauke May, Jennifer Krupka, Marion Fries, Ina Thielmann, Ingo Pragst, Thomas Weimer, Con Panousis, Bernhard Nieswandt, Guido Stoll, Gerhard Dickneite, Stefan Schulte, Marc W. Nolte Tags: Research Paper Source Type: research